Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

Also called NCT02002923

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02002923
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02002923. Randomized; double masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2015-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation
Condition
Paroxysmal Atrial Fibrillation
Condition
Persistent Atrial Fibrillation
Intervention (Procedure)
Pulmonary vein isolation
Intervention (Drug)
Botulinum Toxin
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation (class: research network)

Record details

Record id
cardio:ct-nct02002923
Content hash
b8e4e79d5446e10c15acb70b08198547d134ffe57fbd38a0bfc2c687a870006f